Cargando…

The Incidence of Port-Site Metastases in Gynecologic Cancers

OBJECTIVES: To determine the incidence of port-site metastases in patients undergoing laparoscopic procedures for gynecologic cancers. METHODS: The charts of patients treated by laparoscopy for diagnosis, treatment, or staging of gynecologic cancers by the academic faculty attending physicians were...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagarsheth, Nimesh P., Rahaman, Jamal, Cohen, Carmel J., Gretz, Herb, Nezhat, Farr
Formato: Texto
Lenguaje:English
Publicado: Society of Laparoendoscopic Surgeons 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3015524/
https://www.ncbi.nlm.nih.gov/pubmed/15119657
_version_ 1782195535611953152
author Nagarsheth, Nimesh P.
Rahaman, Jamal
Cohen, Carmel J.
Gretz, Herb
Nezhat, Farr
author_facet Nagarsheth, Nimesh P.
Rahaman, Jamal
Cohen, Carmel J.
Gretz, Herb
Nezhat, Farr
author_sort Nagarsheth, Nimesh P.
collection PubMed
description OBJECTIVES: To determine the incidence of port-site metastases in patients undergoing laparoscopic procedures for gynecologic cancers. METHODS: The charts of patients treated by laparoscopy for diagnosis, treatment, or staging of gynecologic cancers by the academic faculty attending physicians were studied from July 1, 1997 to June 30, 2001. No patient without a histological or cytological diagnosis of cancer from the index procedure were included. Fisher's exact test was used for statistical analysis. RESULTS: Eighty-three patients were identified accounting for 87 procedures. Types of cancer treated included endometrial (39), ovarian (29), and cervical (14). Twenty procedures were performed for recurrence of ovarian or peritoneal cancer, and ascites was present in 10 cases. Port-site metastases occurred in 2 patients accounting for 8 sites. Five sites were diagnosed in a single patient 13 days after a second-look laparoscopy for stage IIIB ovarian cancer, and 3 sites were diagnosed in a patient 46 days after an interval laparoscopy for stage IIIC primary peritoneal cancer. Ascites was present in both patients. The overall incidences of port-site metastases per procedure and per port placed were 2.3% (2/87) and 2.4% (8/330), respectively. In patients with a recurrence of ovarian or peritoneal cancer, no port-site metastases (0/16) occurred in the absence of ascites, whereas 50% (2/4) of patients with ascites developed port-site metastases (P<.035). CONCLUSIONS: The overall incidence of port-site metastases in gynecologic cancers in our study was 2.3%. The risk of port-site metastases is highest (50%) in patients with recurrence of ovarian or primary peritoneal malignancies undergoing procedures in the presence of ascites.
format Text
id pubmed-3015524
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Society of Laparoendoscopic Surgeons
record_format MEDLINE/PubMed
spelling pubmed-30155242011-02-17 The Incidence of Port-Site Metastases in Gynecologic Cancers Nagarsheth, Nimesh P. Rahaman, Jamal Cohen, Carmel J. Gretz, Herb Nezhat, Farr JSLS Scientific Papers OBJECTIVES: To determine the incidence of port-site metastases in patients undergoing laparoscopic procedures for gynecologic cancers. METHODS: The charts of patients treated by laparoscopy for diagnosis, treatment, or staging of gynecologic cancers by the academic faculty attending physicians were studied from July 1, 1997 to June 30, 2001. No patient without a histological or cytological diagnosis of cancer from the index procedure were included. Fisher's exact test was used for statistical analysis. RESULTS: Eighty-three patients were identified accounting for 87 procedures. Types of cancer treated included endometrial (39), ovarian (29), and cervical (14). Twenty procedures were performed for recurrence of ovarian or peritoneal cancer, and ascites was present in 10 cases. Port-site metastases occurred in 2 patients accounting for 8 sites. Five sites were diagnosed in a single patient 13 days after a second-look laparoscopy for stage IIIB ovarian cancer, and 3 sites were diagnosed in a patient 46 days after an interval laparoscopy for stage IIIC primary peritoneal cancer. Ascites was present in both patients. The overall incidences of port-site metastases per procedure and per port placed were 2.3% (2/87) and 2.4% (8/330), respectively. In patients with a recurrence of ovarian or peritoneal cancer, no port-site metastases (0/16) occurred in the absence of ascites, whereas 50% (2/4) of patients with ascites developed port-site metastases (P<.035). CONCLUSIONS: The overall incidence of port-site metastases in gynecologic cancers in our study was 2.3%. The risk of port-site metastases is highest (50%) in patients with recurrence of ovarian or primary peritoneal malignancies undergoing procedures in the presence of ascites. Society of Laparoendoscopic Surgeons 2004 /pmc/articles/PMC3015524/ /pubmed/15119657 Text en © 2004 by JSLS, Journal of the Society of Laparoendoscopic Surgeons This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits for noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited and is not altered in any way.
spellingShingle Scientific Papers
Nagarsheth, Nimesh P.
Rahaman, Jamal
Cohen, Carmel J.
Gretz, Herb
Nezhat, Farr
The Incidence of Port-Site Metastases in Gynecologic Cancers
title The Incidence of Port-Site Metastases in Gynecologic Cancers
title_full The Incidence of Port-Site Metastases in Gynecologic Cancers
title_fullStr The Incidence of Port-Site Metastases in Gynecologic Cancers
title_full_unstemmed The Incidence of Port-Site Metastases in Gynecologic Cancers
title_short The Incidence of Port-Site Metastases in Gynecologic Cancers
title_sort incidence of port-site metastases in gynecologic cancers
topic Scientific Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3015524/
https://www.ncbi.nlm.nih.gov/pubmed/15119657
work_keys_str_mv AT nagarshethnimeshp theincidenceofportsitemetastasesingynecologiccancers
AT rahamanjamal theincidenceofportsitemetastasesingynecologiccancers
AT cohencarmelj theincidenceofportsitemetastasesingynecologiccancers
AT gretzherb theincidenceofportsitemetastasesingynecologiccancers
AT nezhatfarr theincidenceofportsitemetastasesingynecologiccancers
AT nagarshethnimeshp incidenceofportsitemetastasesingynecologiccancers
AT rahamanjamal incidenceofportsitemetastasesingynecologiccancers
AT cohencarmelj incidenceofportsitemetastasesingynecologiccancers
AT gretzherb incidenceofportsitemetastasesingynecologiccancers
AT nezhatfarr incidenceofportsitemetastasesingynecologiccancers